BACKGROUND: Biomarkers may play an important role in identifying patients at risk for cancer therapy cardiotoxicity. Our objectives were to define the patterns of change in biomarkers with cancer therapy and their associations with cardiotoxicity. METHODS: In a multicenter cohort of 78 breast cancer patients undergoing doxorubicin and trastuzumab therapy, 8 biomarkers were evaluated at baseline and every 3 months over a maximum follow-up of 15 months. These biomarkers, hypothesized to be mechanistically relevant to cardiotoxicity, included high-sensitivity cardiac troponin I (hs-cTnI), high-sensitivity C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), growth differentiation factor 15 (GDF-15), myeloperoxidase (MPO), placental growth factor (PlGF), soluble fms-like tyrosine kinase receptor-1 (sFlt-1), and galectin 3 (gal-3). We determined if biomarker increases were associated with cardiotoxicity at the same visit and the subsequent visit over the entire course of therapy. Cardiotoxicity was defined by the Cardiac Review and Evaluation Criteria; alternative definitions were also considered. RESULTS: Across the entire cohort, all biomarkers except NT-proBNP and gal-3 demonstrated increases by 3 months; these increases persisted for GDF-15, PlGF, and hs-cTnI at 15 months. Increases in MPO, PlGF, and GDF-15 were associated with cardiotoxicity at the same visit [MPO hazard ratio 1.38 (95% CI 1.10-1.71), P = 0.02; PlGF 3.78 (1.30-11.0), P = 0.047; GDF-15 1.71 (1.15-2.55), P = 0.01] and the subsequent visit. MPO was robust to alternative outcome definitions. CONCLUSIONS: Increases in MPO are associated with cardiotoxicity over the entire course of doxorubicin and trastuzumab therapy. Assessment with PlGF and GDF-15 may also be of value. These findings motivate validation studies in additional cohorts.
BACKGROUND: Biomarkers may play an important role in identifying patients at risk for cancer therapy cardiotoxicity. Our objectives were to define the patterns of change in biomarkers with cancer therapy and their associations with cardiotoxicity. METHODS: In a multicenter cohort of 78 breast cancerpatients undergoing doxorubicin and trastuzumab therapy, 8 biomarkers were evaluated at baseline and every 3 months over a maximum follow-up of 15 months. These biomarkers, hypothesized to be mechanistically relevant to cardiotoxicity, included high-sensitivity cardiac troponin I (hs-cTnI), high-sensitivity C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), growth differentiation factor 15 (GDF-15), myeloperoxidase (MPO), placental growth factor (PlGF), soluble fms-like tyrosine kinase receptor-1 (sFlt-1), and galectin 3 (gal-3). We determined if biomarker increases were associated with cardiotoxicity at the same visit and the subsequent visit over the entire course of therapy. Cardiotoxicity was defined by the Cardiac Review and Evaluation Criteria; alternative definitions were also considered. RESULTS: Across the entire cohort, all biomarkers except NT-proBNP and gal-3 demonstrated increases by 3 months; these increases persisted for GDF-15, PlGF, and hs-cTnI at 15 months. Increases in MPO, PlGF, and GDF-15 were associated with cardiotoxicity at the same visit [MPO hazard ratio 1.38 (95% CI 1.10-1.71), P = 0.02; PlGF 3.78 (1.30-11.0), P = 0.047; GDF-15 1.71 (1.15-2.55), P = 0.01] and the subsequent visit. MPO was robust to alternative outcome definitions. CONCLUSIONS: Increases in MPO are associated with cardiotoxicity over the entire course of doxorubicin and trastuzumab therapy. Assessment with PlGF and GDF-15 may also be of value. These findings motivate validation studies in additional cohorts.
Authors: Maria T Sandri; Michela Salvatici; Daniela Cardinale; Laura Zorzino; Rita Passerini; Paola Lentati; Maria Leon; Maurizio Civelli; Giovanni Martinelli; Carlo M Cipolla Journal: Clin Chem Date: 2005-06-02 Impact factor: 8.327
Authors: Heloisa Sawaya; Igal A Sebag; Juan Carlos Plana; James L Januzzi; Bonnie Ky; Victor Cohen; Sucheta Gosavi; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie Journal: Am J Cardiol Date: 2011-03-02 Impact factor: 2.778
Authors: Thomas Eschenhagen; Thomas Force; Michael S Ewer; Gilles W de Keulenaer; Thomas M Suter; Stefan D Anker; Metin Avkiran; Evandro de Azambuja; Jean-Luc Balligand; Dirk L Brutsaert; Gianluigi Condorelli; Arne Hansen; Stephane Heymans; Joseph A Hill; Emilio Hirsch; Denise Hilfiker-Kleiner; Stefan Janssens; Steven de Jong; Gitte Neubauer; Burkert Pieske; Piotr Ponikowski; Munir Pirmohamed; Mathias Rauchhaus; Douglas Sawyer; Peter H Sugden; Johann Wojta; Faiez Zannad; Ajay M Shah Journal: Eur J Heart Fail Date: 2011-01 Impact factor: 15.534
Authors: Bonnie Ky; Mary Putt; Heloisa Sawaya; Benjamin French; James L Januzzi; Igal A Sebag; Juan Carlos Plana; Victor Cohen; Jose Banchs; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie Journal: J Am Coll Cardiol Date: 2013-11-27 Impact factor: 24.094
Authors: Christopher G Willett; Dan G Duda; Emmanuelle di Tomaso; Yves Boucher; Marek Ancukiewicz; Dushyant V Sahani; Johanna Lahdenranta; Daniel C Chung; Alan J Fischman; Gregory Y Lauwers; Paul Shellito; Brian G Czito; Terence Z Wong; Erik Paulson; Martin Poleski; Zeljko Vujaskovic; Rex Bentley; Helen X Chen; Jeffrey W Clark; Rakesh K Jain Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Federica Accornero; Jop H van Berlo; Matthew J Benard; John N Lorenz; Peter Carmeliet; Jeffery D Molkentin Journal: Circ Res Date: 2011-06-02 Impact factor: 17.367
Authors: Ali Agha; Abdulrazzak Zarifa; Peter Kim; Cezar Iliescu; Greg Gladish; Saamir Hassan; Nicolas Palaskas; Jean B Durand; Yang Lu; Juan Lopez-Mattei Journal: Methodist Debakey Cardiovasc J Date: 2019 Oct-Dec